Applications of Proteomics, Glycomics, and Metabolomics Analyses in Systemic Lupus Erythematosus.

IF 2.3 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current drug metabolism Pub Date : 2025-11-04 DOI:10.2174/0113892002430185251015075018

Rui Xu, Guosong Zhang, Shifang Wang, Tao Yang, Canjian Wang

{"title":"Applications of Proteomics, Glycomics, and Metabolomics Analyses in Systemic Lupus Erythematosus.","authors":"Rui Xu, Guosong Zhang, Shifang Wang, Tao Yang, Canjian Wang","doi":"10.2174/0113892002430185251015075018","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic Lupus Erythematosus (SLE) is a multifactorial autoimmune disorder in-fluenced by genetic predisposition, immune dysregulation, environmental triggers, and epi-genetic modifications. Despite advances in treatment, many patients experience recurrent symptoms and adverse effects. Recent large-scale studies have revealed significant alterations in proteins, glycopeptides, and metabolites in SLE, deepening our understanding of its path-ogenesis. Emerging omics technologies, such as proteomics, glycomics, and metabolomics, enable the high-throughput identification of disease-related biomarkers. However, biological processes are typically driven by the interplay among multiple molecular layers. Therefore, integrative multi-omics approaches have become essential for uncovering potential bi-omarkers and risk factors. This review summarizes the classification of SLE biomarkers and recent advances in diagnostic applications across proteomics, glycomics, and metabolomics, aiming to support the development of more precise diagnostic strategies for SLE.</p>","PeriodicalId":10770,"journal":{"name":"Current drug metabolism","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892002430185251015075018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Systemic Lupus Erythematosus (SLE) is a multifactorial autoimmune disorder in-fluenced by genetic predisposition, immune dysregulation, environmental triggers, and epi-genetic modifications. Despite advances in treatment, many patients experience recurrent symptoms and adverse effects. Recent large-scale studies have revealed significant alterations in proteins, glycopeptides, and metabolites in SLE, deepening our understanding of its path-ogenesis. Emerging omics technologies, such as proteomics, glycomics, and metabolomics, enable the high-throughput identification of disease-related biomarkers. However, biological processes are typically driven by the interplay among multiple molecular layers. Therefore, integrative multi-omics approaches have become essential for uncovering potential bi-omarkers and risk factors. This review summarizes the classification of SLE biomarkers and recent advances in diagnostic applications across proteomics, glycomics, and metabolomics, aiming to support the development of more precise diagnostic strategies for SLE.

查看原文本刊更多论文

蛋白质组学、糖组学和代谢组学分析在系统性红斑狼疮中的应用。

系统性红斑狼疮（SLE）是一种多因素自身免疫性疾病，受遗传易感性、免疫失调、环境触发和表观遗传修饰的影响。尽管治疗取得了进展，但许多患者仍会出现复发症状和不良反应。最近的大规模研究揭示了SLE中蛋白质、糖肽和代谢物的显著改变，加深了我们对其发病机制的理解。新兴的组学技术，如蛋白质组学、糖组学和代谢组学，使疾病相关生物标志物的高通量鉴定成为可能。然而，生物过程通常是由多个分子层之间的相互作用驱动的。因此，综合多组学方法对于发现潜在的双标记物和危险因素至关重要。本文综述了SLE生物标志物的分类以及蛋白质组学、糖组学和代谢组学在SLE诊断应用中的最新进展，旨在支持SLE更精确诊断策略的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug metabolism 医学-生化与分子生物学

CiteScore

4.30

自引率

4.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism. More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.